Patents Represented by Attorney, Agent or Law Firm Gregory D. Williams
  • Patent number: 7029900
    Abstract: In accordance with the present invention, there is provided a novel restriction endonuclease obtainable from Bacillus thermoglucosidasius 36A (NEB#1384), hereinafter referred to as “BtgZI”, which endonuclease: (1) recognizes the nucleotide sequence 5?-GCGATG-3? in a double-stranded DNA molecule as shown below, 5?-GCGATGNNNNNNNNNN?-3? (SEQ ID NO:9) 3?-CGCTACNNNNNNNNNNNNNN?-5? ?(wherein G represents guanine, C represents cytosine, A represents adenine, T represents thymine and N represents either G, C, A, or T); (2) cleaves said sequence in the phosphodiester bonds between the 10th and the 11th nucleotides 3? to the recognition sequence in the 5?-GCGATG-3 strand of the DNA, and between the 14th and 15th nucleotides 5? to the recognition sequence in the complement stand, 5?-CATCGC-3?, to produce a 4 base 5? extension; and (3) cleaves double-stranded pBR322 DNA to produce 3 fragments of 2892, 1181 and 288 base pairs.
    Type: Grant
    Filed: July 10, 2003
    Date of Patent: April 18, 2006
    Assignee: New England Biolabs, Inc.
    Inventors: Richard D. Morgan, Paul Walsh
  • Patent number: 7011966
    Abstract: The present invention relates to recombinant DNA encoding the AcuI restriction endonuclease as well as AcuI methylase, and expression of AcuI restriction endonuclease and AcuI methylase in E. coli cells containing the recombinant DNA.
    Type: Grant
    Filed: April 16, 2003
    Date of Patent: March 14, 2006
    Assignee: New England Biolabs, Inc.
    Inventors: James Samuelson, Shuang-yong Xu, Diana O'Loane
  • Patent number: 6919194
    Abstract: The present invention relates to recombinant DNA which encodes the Tth111II restriction endonuclease-methylase fusion protein (Tth111IIRM), expression of Tth111II restriction endonuclease-methylase fusion protein in E. coli cells containing the recombinant DNA, and purification of Tth111II endonuclease-methylase fusion protein to near homogeneity.
    Type: Grant
    Filed: January 8, 2003
    Date of Patent: July 19, 2005
    Assignee: New England Biolabs, Inc.
    Inventors: Zhenyu Zhu, Derek Robinson, Jack Benner, Shuang-yong Xu
  • Patent number: 6905837
    Abstract: A method is provided for identifying a restriction endonuclease, which includes the steps of (a) screening a target DNA sequence for the presence of known methylase sequence motifs, (b) identifying any open reading frames which lie close to the methylase sequence motifs screened in step (a), and (c) assaying the protein products of these open reading frames for restriction endonuclease activity. Methods for identifying isoschizomers of known restriction endonucleases, which isoschizomers possess a desired physical property, such as thermostability, are also provided by the present invention, as are several novel restriction endonucleases isolated from M. jannaschii, MjaIII and MjaIV. Additionally, a gene was identified that encoded a previously observed endonuclease activity, designated MjaII. Also provided by the present invention are vectors suitable for cloning a DNA sequence encoding a cytotoxic protein, via independent transcription promotors which may be selectively controlled by several conditions.
    Type: Grant
    Filed: July 30, 2002
    Date of Patent: June 14, 2005
    Assignee: New England Biolabs, Inc.
    Inventors: Richard J. Roberts, Devon R. Byrd, Richard D. Morgan, Jay Patti, Christopher J. Noren
  • Patent number: 6869786
    Abstract: The present invention relates to recombinant DNA encoding the BsrGI restriction endonuclease as well as BsrGI methyltransferase, expression of BsrGI restriction endonuclease and BsrGI methyltransferase in E. coli cells containing the recombinant DNA.
    Type: Grant
    Filed: January 8, 2003
    Date of Patent: March 22, 2005
    Assignee: New England Biolabs, Inc.
    Inventors: Ningyuan Fang, Shuang-yong Xu
  • Patent number: 6815537
    Abstract: The present invention relates to cloned DNA containing origin of DNA replication and to cloned DNA encoding repliation protein, RepT.
    Type: Grant
    Filed: September 18, 2000
    Date of Patent: November 9, 2004
    Assignee: New England Biolabs, Inc.
    Inventors: Jay Wayne, Shuang-yong Xu
  • Patent number: 6794172
    Abstract: The present invention relates to recombinant DNA encoding the PpuMI restriction endonuclease as well as PpuMI methylase, expression of PpuMI restriction endonuclease and PpuMI methylase in E. coli cells containing the recombinant DNA.
    Type: Grant
    Filed: May 17, 2002
    Date of Patent: September 21, 2004
    Assignee: New England Biolabs, Inc.
    Inventors: James Samuelson, Shuang-yong Xu
  • Patent number: 6790630
    Abstract: In accordance with the present invention, a 31-33 kDa glycoprotein of D. immitis (DiT33) is provided which represents another member of the family of putative pepsin inhibitors. Other known members include Ov33 (a.k.a. Ov33.3, Oc3.6, OvD 5B), Bm33 and Av33. These filarial molecules possess significant homology to the known pepsin inhibitor (Aspi3) of A. suum. Using DiT33 or Ov33, in the form of a recombinant fusion or non-fusion protein, antibody responses to DiT33 may be monitored and used in immunodiagnosis of heartworm infection in mammals. Antibodies reactive with the DiT33 or Ov33 may also be used to detect DiT33 antigen as a means of immunodiagnosis of heartworm infection in mammals.
    Type: Grant
    Filed: March 23, 2000
    Date of Patent: September 14, 2004
    Assignee: New England Biolabs, Inc.
    Inventors: Clotilde K. S. Carlow, Francine B. Perler, XiaQiang Hong, Jhon Santiago Mejia
  • Patent number: 6764843
    Abstract: The present invention relates to recombinant DNA that encodes the BsmBI restriction endonuclease as well as BsmBI methyltransferase, expression of BsmBI restriction endonuclease and BsmBI methylase in E. coli cells containing the recombinant DNA. It also relates to a method for purification of the recombinant BsmBI restriction endonuclease.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: July 20, 2004
    Assignee: New England Biolabs, Inc.
    Inventors: Shuang-yong Xu, Andrew Dore, Adam Hume, John Pelletier, Jing Zhou
  • Patent number: 6723546
    Abstract: The present invention relates to recombinant DNA which encodes the BsaI restriction endonuclease as well as BsaI methylase, expression of BsaI restriction endonuclease and BsaI methylase in E. coli cells containing the recombinant DNA, and purification of BsaI restriction endonuclease to near homogeneity.
    Type: Grant
    Filed: March 26, 2002
    Date of Patent: April 20, 2004
    Assignee: New England Biolabs, Inc.
    Inventors: Zhenyu Zhu, Shuang-Yong Xu
  • Patent number: 6689573
    Abstract: A method is provided for identifying a restriction endonuclease that includes: screening a target DNA sequence for the presence of known methylase sequence motifs, identifying any open reading frames which lie close to the screened methylase sequence motif and assaying the protein products of the open reading frames for restriction endonuclease activity.
    Type: Grant
    Filed: May 24, 2000
    Date of Patent: February 10, 2004
    Assignee: New England Biolabs, Inc.
    Inventors: Richard J. Roberts, Devon R. Byrd, Richard D. Morgan, Jay Patti, Christopher J. Noren
  • Patent number: 6673588
    Abstract: The present invention relates to recombinant DNA coding for the MspA1I restriction endonuclease as well as MspA1I methylase, expression of MspA1I restriction endonuclease and MspA1I methylase in E. coli cells containing the recombinant DNA.
    Type: Grant
    Filed: February 26, 2002
    Date of Patent: January 6, 2004
    Assignee: New England Biolabs, Inc.
    Inventors: Shuang-yong Xu, Robert Maunus, Katy Stropnicky
  • Patent number: 6660475
    Abstract: The present invention relates to the use of site-specific nucleic acid nicking enzymes to create single-stranded regions in duplex nucleic acids. Such single-stranded regions can take the form of gaps interior to the duplex, or terminal single-stranded regions. Single-stranded termini can be crafted to allow linkage of various elements via base-pairing with elements containing a complementary single-stranded region. This joining is useful, for example, in an ordered, oriented assembly of DNA modules to create cloning or expression vectors. This joining is also useful in attaching detection probes and purifying DNA molecules containing the single-stranded region. Gaps are useful in similar applications, including attaching detection or purification probes.
    Type: Grant
    Filed: December 15, 2000
    Date of Patent: December 9, 2003
    Assignee: New England Biolabs, Inc.
    Inventors: William E. Jack, Ira Schildkraut, Julie Forney Menin
  • Patent number: 6649395
    Abstract: The present invention relates to the use of these cyclophilins, hereinafter referred to as ‘tyrosine-containing’ cyclophilins, in a method for identifying compounds capable of binding to and/or inhibiting the enzymatic activity of these proteins. Such compounds may be further screened for their ability to inhibit parasites which are not susceptible to the anti-parasitic effects of CsA.
    Type: Grant
    Filed: November 17, 2000
    Date of Patent: November 18, 2003
    Assignee: New England Biolabs, Inc.
    Inventors: Clotilde K. S. Carlow, Xiqiang Hong, Dong Ma
  • Patent number: 6596524
    Abstract: The present invention relates to recombinant DNA which encodes the BsmAI restriction endonuclease as well as BsmAI methylase, expression of BsmAI restriction endonuclease and BsmAI methylase in E. coli cells containing the recombinant DNA, and purification of BsmAI endonuclease to near homogeneity.
    Type: Grant
    Filed: September 20, 2001
    Date of Patent: July 22, 2003
    Assignee: New England Biolabs, Inc.
    Inventors: Zhenyu Zhu, Jing Zhou, Shuang-yong Xu
  • Patent number: 6593122
    Abstract: The present invention relates to recombinant DNA that encodes the BseRI restriction endonuclease as well as M.BseRI, expression of BseRI restriction endonuclease and M.BseRI in E. coli cells containing the recombinant DNA.
    Type: Grant
    Filed: October 11, 2001
    Date of Patent: July 15, 2003
    Assignee: New England Biolabs, Inc.
    Inventors: Shuang-yong Xu, Robert Maunus, Jack Benner
  • Patent number: 6589769
    Abstract: The present invention relates to recombinant DNA that encodes the TspRI restriction endonuclease as well as TspRI methylase, expression of TspRI restriction endonuclease and TspRI methylase in E. coli cells containing the recombinant DNA.
    Type: Grant
    Filed: October 19, 2001
    Date of Patent: July 8, 2003
    Assignee: New England Biolabs, Inc.
    Inventors: Shuang-yong Xu, Andrew Dore, Michael Dalton, Jack Benner
  • Patent number: 6586220
    Abstract: The present invention relates to recombinant DNA encoding the BsaWI restriction endonuclease as well as BsaWI methylase, expression of BsaWI restriction endonuclease and BsaWI methylase in E. coli cells containing the recombinant DNA.
    Type: Grant
    Filed: February 26, 2002
    Date of Patent: July 1, 2003
    Assignee: New England Biolabs, Inc.
    Inventors: Shuang-yong Xu, Jing Zhou, Adam Hume, Robert Maunus
  • Patent number: 6569669
    Abstract: The present invention relates to host cells suitable for expressing genes under the direction of foreign RNA polymerases and to providing very low levels of expression of such genes and RNA polymerases in the absence of induction.
    Type: Grant
    Filed: October 12, 2000
    Date of Patent: May 27, 2003
    Assignee: New England Biolabs, Inc.
    Inventor: Elisabeth A. Raleigh
  • Patent number: 6521425
    Abstract: In accordance with the present invention, there are provided selection systems and methods for screening for agents that control splicing of inteins in their native host protein (extein) or in homologous exteins. Specifically, there are provided positive genetic selection systems for the screening of agents which inhibit or activate protein splicing which comprise: a host cell containing a chromosomal gene encoding either a drug-resistant form of a target enzyme or a wild-type target enzyme, and a plasmid-borne gene encoding either a drug-sensitive form of the target enzyme, which is dominantly cytotoxic upon interaction with the drug, or a dominantly cytotoxic form of the target enzyme. In these systems the plasmid-borne gene contains an intein, and the inhibition or activation of splicing of the dominant cytotoxic form of the target enzyme by a given reagent results in the survival or death of the host cell. More specifically, positive genetic selection systems which utilize the M. xenopi GyrA intein or M.
    Type: Grant
    Filed: October 29, 1999
    Date of Patent: February 18, 2003
    Assignee: New England Biolabs, Inc.
    Inventors: Francine B. Perler, Eric E. Adam